{"entity":{"id":"salvatore-siena","kind":"person","name":"Salvatore Siena","aka":[],"tldr":"Milan oncologist who co-led HERACLES and was lead author of DESTINY-CRC01, which showed trastuzumab deruxtecan is active in HER2-positive colorectal cancer, and a leader of the anti-EGFR antibody trials in the disease.","summary":"Salvatore Siena is professor of medical oncology at the University of Milan and led the Niguarda Cancer Center's oncology programme. He was a senior investigator of HERACLES and first author of the 2021 Lancet Oncology report of DESTINY-CRC01, the phase 2 trial in which trastuzumab deruxtecan produced responses in HER2-positive, RAS wild-type metastatic colorectal cancer after standard therapy. He was also a lead investigator of the panitumumab trials that established RAS testing before anti-EGFR treatment.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/Salvatore_Siena","links":[],"tags":["colorectal","targeted-therapy","trialist"],"related":[],"cancers":["her2-amplified-colorectal","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["niguarda-cancer-center"],"pathways":[],"terms":[],"trials":["heracles"],"people":[],"bottlenecks":[],"keyPapers":["paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021"],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology, University of Milan, and Niguarda Cancer Center","institutionId":"niguarda-cancer-center","specialisms":["Colorectal cancer","HER2-directed therapy","Anti-EGFR therapy"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Siena%5BAuthor%5D"}],"papers":[{"title":"DESTINY-CRC01: trastuzumab deruxtecan in HER2-expressing metastatic colorectal cancer","journal":"The Lancet Oncology","year":2021,"url":"https://doi.org/10.1016/S1470-2045(21)00086-3","doi":"10.1016/S1470-2045(21)00086-3"}],"orcid":"0000-0002-2681-2846"},"route":"/people/salvatore-siena/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"her2-amplified-colorectal","kind":"cancer","name":"HER2-amplified colorectal cancer","route":"/cancers/her2-amplified-colorectal/"}],"institution":[{"id":"niguarda-cancer-center","kind":"institution","name":"Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda","route":"/institutions/niguarda-cancer-center/"}],"trial":[{"id":"heracles","kind":"trial","name":"HERACLES","route":"/trials/heracles/"}],"paper":[{"id":"paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015","kind":"paper","name":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","route":"/key-papers/paper-valtorta-her2-scoring-colorectal-heracles-mod-pathol-2015/"},{"id":"paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016","kind":"paper","name":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES)","route":"/key-papers/paper-sartore-bianchi-heracles-trastuzumab-lapatinib-lancet-oncol-2016/"},{"id":"paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012","kind":"paper","name":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","route":"/key-papers/paper-misale-kras-acquired-resistance-anti-egfr-colorectal-nature-2012/"},{"id":"paper-douillard-prime-panitumumab-ras-nejm-2013","kind":"paper","name":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer (PRIME)","route":"/key-papers/paper-douillard-prime-panitumumab-ras-nejm-2013/"},{"id":"paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021","kind":"paper","name":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01)","route":"/key-papers/paper-siena-destiny-crc01-trastuzumab-deruxtecan-lancet-oncol-2021/"},{"id":"paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023","kind":"paper","name":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER)","route":"/key-papers/paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023/"}]}}